These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 36177801)

  • 1. Energy balance-related factors in childhood and adolescence and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.
    Jenniskens JCA; Offermans K; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    Mol Carcinog; 2022 Dec; 61(12):1099-1115. PubMed ID: 36177801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status.
    Jenniskens JCA; Offermans K; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2723-2742. PubMed ID: 35546360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between mutational subgroups, Warburg-subtypes, and survival in patients with colorectal cancer.
    Offermans K; Jenniskens JCA; Simons CCJM; Samarska I; Fazzi GE; van der Meer JRM; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    Cancer Med; 2023 Jan; 12(2):1137-1156. PubMed ID: 35785488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations.
    Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J
    PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Energy balance-related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg-effect.
    Jenniskens JCA; Offermans K; Simons CCJM; Samarska I; Fazzi GE; Smits KM; Schouten LJ; Weijenberg MP; Grabsch HI; van den Brandt PA
    Int J Cancer; 2022 Jun; 150(11):1812-1824. PubMed ID: 35064924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer.
    Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C
    World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E; Pratt S; Blosser W; Dowless M; Simpson N; Yuan XJ; Jaken S; Manro J; Stephens J; Zhang Y; Huber L; Peng SB; Stancato LF
    Oncotarget; 2017 Feb; 8(6):9251-9266. PubMed ID: 27999210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.
    Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR
    Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and coexistence of KRAS, NRAS, BRAF and PIK3CA mutations and occurrence of MMR deficiency in Danish colorectal cancer patients.
    Poulsen TS; de Oliveira DVNP; Espersen MLM; Klarskov LL; Skovrider-Ruminski W; Hogdall E
    APMIS; 2021 Feb; 129(2):61-69. PubMed ID: 33075161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients.
    Ye JX; Liu Y; Qin Y; Zhong HH; Yi WN; Shi XY
    World J Gastroenterol; 2015 Feb; 21(5):1595-605. PubMed ID: 25663779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and characteristics of
    Li W; Qiu T; Dong L; Zhang F; Guo L; Ying J
    J Cancer; 2020; 11(13):3827-3833. PubMed ID: 32328187
    [No Abstract]   [Full Text] [Related]  

  • 14. [Difference analysis of somatic mutations between deficient mismatch repair and proficient mismatch repair gene related with colorectal cancer].
    Tang XJ; Yang MY; Zhu LZ; Xu D; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2021 Oct; 43(10):1088-1093. PubMed ID: 34695900
    [No Abstract]   [Full Text] [Related]  

  • 15. Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study.
    Brändstedt J; Wangefjord S; Nodin B; Eberhard J; Sundström M; Manjer J; Jirström K
    PLoS One; 2014; 9(2):e98964. PubMed ID: 24918610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.
    Hutchins G; Southward K; Handley K; Magill L; Beaumont C; Stahlschmidt J; Richman S; Chambers P; Seymour M; Kerr D; Gray R; Quirke P
    J Clin Oncol; 2011 Apr; 29(10):1261-70. PubMed ID: 21383284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
    Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
    BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
    Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
    Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ
    J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China.
    Lian SY; Tan LX; Liu XZ; Yang LJ; Li NN; Feng Q; Wang P; Wang Y; Qiao DB; Zhou LX; Sun TT; Wang L; Wu AW; Li ZW
    Medicine (Baltimore); 2023 Mar; 102(9):e33115. PubMed ID: 36862900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.